Ligand Pharma (LGND) Tops Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Ligand Reports First Quarter 2015 Financial Results
May 11, 2015 8:31 AM EDTConference Call Begins at 9:00 a.m. Eastern Time Today
SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2015, and provided an operating forecast and program updates.
Financial highlights for the first quarter of 2015 include:
Total revenues were $14.6 million and royalty revenues were $10.3 million, an increase of 31% compared with the first quarter of 2014 Adjusted EPS was $0.33 and GAAP EPS was $0.04 The company generated operating cash of $7.6 million, a significant... MoreLigand Acquires Rights to More Than 15 Fully-Funded Development Programs from Selexis SA
May 11, 2015 8:15 AM EDTLigands Portfolio of Fully-Funded Partnered Assets Now Exceeds 120
SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has acquired a portfolio of potential future milestone and royalty payments for more than 15 biologic development programs from Selexis SA for $4 million in cash. Highlights of the transaction include the following:
The basis for the development programs and economic rights is a proprietary technology for manufacturing stable and high performing mammalian cell lines for biologic therapeutics The acquired assets include a mix of novel biologics and biosimilars... More